| Assessment Status | Awaiting full HTA submission from Applicant |
| HTA ID | 24032 |
| Drug | Amivantamab |
| Brand | Rybrevant® |
| Indication | Amivantamab (Rybrevant®) in combination with carboplatin and pemetrexed is indicated for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon 20 insertion |
| Assessment Process | |
| Rapid review commissioned | 31/07/2024 |
| Rapid review completed | 30/09/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of amivantamab for this indication compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 30/10/2024 |
| Pre-submission consultation with Applicant | 03/12/2024 |
